Nivolumab not recommended for recurrent or metastatic head and neck cancer
If NICE draft recommendation does not change following public consultation, the treatment will be removed from the CDF on publication of the final guidance.
Join OnMedica and benefit from:
- Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
- High-quality, evidence-based content developed by expert editors and clinicians
- Articles, quizzes, videos, visual summaries and more
- Regulatory alerts and round-up of medical journals
- New content added daily, so you know you’re always up to date